Global Gleevec Market Size By Type (100mg, 400mg), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Gleevec Market was valued at USD 4.3 billion in 2023 and is projected to reach USD 6.9 billion by 2031, growing at a CAGR of 6.1% during the forecast period from 2023 to 2031. Gleevec (imatinib mesylate), a targeted therapy used primarily for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), has played a transformative role in oncology by improving survival rates and quality of life. The market growth is driven by increasing cancer prevalence, expanding off-label usage, and growing access to oncology treatments in emerging markets.

Drivers:

1. Rising Incidence of Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GISTs):

The increasing global burden of hematological malignancies and rare tumors is driving demand for effective targeted therapies like Gleevec, which has demonstrated superior long-term efficacy.

2. Expanding Applications in Off-label Indications:

Clinicians are exploring the use of Gleevec beyond CML and GISTs, including dermatofibrosarcoma protuberans and hypereosinophilic syndrome, which broadens its therapeutic reach.

3. Favorable Reimbursement and Healthcare Access Initiatives:

Developed markets offer robust insurance coverage, and global health initiatives are improving access in low- and middle-income countries, further supporting Gleevec's uptake.

Restraints:

1. Patent Expiry and Generic Competition:

The loss of exclusivity has led to the introduction of generics, putting downward pressure on pricing and brand loyalty, thereby restraining revenue growth.

2. Availability of Newer Targeted Therapies:

Emergence of next-generation tyrosine kinase inhibitors (TKIs) such as dasatinib and nilotinib is shifting prescribing preferences, especially for patients who develop resistance to imatinib.

Opportunity:

1. Market Penetration in Emerging Economies:

Low diagnosis rates and unmet medical needs in developing countries represent untapped opportunities for both branded and generic versions of Gleevec.

2. Combination Therapies and Ongoing Research:

Active clinical trials exploring Gleevec in combination with immunotherapies and novel agents may unlock new indications and re-establish its relevance in personalized cancer care.

Market by System Type Insights:

Based on formulation, the oral tablet segment continues to dominate the market, accounting for the highest revenue share in 2023. The convenience, high patient adherence, and well-established dosing regimens of oral Gleevec tablets make them the preferred formulation. The demand for advanced delivery mechanisms such as extended-release tablets is expected to grow moderately.

Market by End-use Insights:

In terms of end use, hospital pharmacies held the largest market share in 2023, driven by hospital-based administration and monitoring of cancer treatments. However, retail and online pharmacies are rapidly gaining ground, particularly in regions with high out-of-pocket healthcare spending, due to improved drug availability and growing patient awareness.

Market by Regional Insights:

North America led the Gleevec market in 2023, supported by high diagnosis rates, well-established cancer care infrastructure, and the presence of major pharmaceutical players. Asia-Pacific, especially India and China, is projected to exhibit the fastest growth during the forecast period, driven by rising cancer incidence, healthcare reforms, and increasing access to generic imatinib.

Competitive Scenario:

Major players in the Global Gleevec Market include Novartis AG (original brand holder), Sun Pharma, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, and Mylan N.V.. These companies focus on price competitiveness, patient assistance programs, and strategic alliances to retain market share.

Key Developments:

2023: Novartis launched a generic-friendly pricing model in Latin America to support broader access post-patent expiry.

2024: Dr. Reddy’s expanded its Gleevec generic portfolio to more than 30 countries with WHO prequalification.

2025: Sun Pharma partnered with local distributors in Southeast Asia to improve oncology drug accessibility.

Scope of Work – Global Gleevec Market

FAQs:

1) What is the current market size of the Global Gleevec Market?

The Global Gleevec Market was valued at USD 4.3 billion in 2023.

2) What is the major growth driver of the Global Gleevec Market?

The rising prevalence of CML and GISTs, along with growing global access to oncology treatments, is the primary driver.

3) Which is the largest region during the forecast period in the Global Gleevec Market?

North America is expected to remain the largest regional market due to advanced healthcare infrastructure and drug availability.

4) Which segment accounted for the largest market share in the Global Gleevec Market?

The oral tablet segment led the market in 2023, favored for its convenience and established efficacy.

5) Who are the key market players in the Global Gleevec Market?

Key players include Novartis AG, Sun Pharma, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries, and Mylan N.V.